Impairing CD62L ligands on recipient LN has minimal impact on GVHD. (A,B) On day 0, WT B6 or GST2/GST3^−/− (B6) (GST) recipients received 1000 cGy and 7 × 10⁶ BM cells with or without 4 × 10⁶ CD4⁺CD25⁻ cells from 129/Sv donors. Mice were killed on days 38 and 41 to collect tissues for histopathologic analyses. (A) Weight curve. †P < .05 for BM controls versus CD4→WT or CD4→GST for all days 24 and later; *P < .05 for CD4→WT versus CD4→GST for all days 14 and later. (B) Liver histopathology. NS indicates not significant for CD4→WT versus CD4→GST; P < .001 for BM controls versus CD4→WT or CD4→GST. (C,D) On day 0, GST recipients received 1000 cGy and 1.3 × 10⁷ BM cells from BALB/c donors with or without 3 × 10⁵ CD4⁺ cells from BALB/c or CCR7^−/− (BALB/c) donors. (C) Survival curve. NS: not significant for WT CD4→GST versus CCR7^−/− CD4→GST; P < .05 for BM controls versus WT CD4→GST or CCR7^−/− CD4→GST. (D) Liver histopathology. NS, not significant for WT CD4→GST versus CCR7^−/− CD4→GST; P < .01 for BM controls versus CD4→WT or CD4→GST.